Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care
DOI: https://doi.org/10.2147/PPA.S271453
2022-07-12
Patient Preference and Adherence
Abstract:Martin O Savage, 1 Luis Fernandez-Luque, 2 Selina Graham, 3 Paula van Dommelen, 4 Matheus Araujo, 5 Antonio de Arriba, 6 Ekaterina Koledova 7 1 Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, London, UK; 2 Adhera Health Inc., Palo Alto, CA, USA; 3 King's College London, London, UK; 4 The Netherlands Organization for Applied Scientific Research TNO, Leiden, the Netherlands; 5 Neurological Institute; Cleveland Clinic, Cleveland, OH, USA; 6 Paediatric Endocrinology, Hospital Universitario Miguel Servet, Zaragoza, Spain; 7 Global Medical Affairs Cardiometabolic & Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany Correspondence: Martin O Savage, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Charterhouse Square, London, EC1M 6BQ, UK, Tel +44 7803084491, Email Pediatric growth hormone (GH) deficiency is a licensed indication for replacement therapy with recombinant human growth hormone (r-hGH). Treatment, consisting of daily subcutaneous injections, extends from the time of diagnosis until cessation of linear growth at completion of puberty. Suboptimal adherence to r-hGH therapy is common and has been well documented to substantially impair the growth response and achievement of the optimal goal which is attainment of adult height within the genetic target range. The causes of poor adherence are complex and include disease-, patient-, doctor-, and treatment-related factors. Interventions for suboptimal adherence are important for a long-term successful outcome and can include both face-to-face and digital strategies. Face-to-face interventions include behavioral change approaches such as motivational interviewing and non-judgmental assessment. Medical and nursing staff require training in these techniques. Digital solutions are rapidly advancing as evidenced by the electronic digital auto-injector device, easypod® (Merck Healthcare KGaA, Darmstadt, Germany), which uses the web-based easypod® connect platform allowing adherence data to be transmitted electronically to healthcare professionals (HCPs), who can then access GH treatment history, enhancing clinical decisions. Over the past 10 years, the multi-national Easypod® Connect Observational Study has reported high levels of adherence (> 85%) from up to 40 countries. The easypod® connect system can be supported by a smartphone app, growlinkTM, which facilitates the interactions between the patients, their care team, and patient support services. HCPs are empowered by new digital techniques, however, the human–digital partnership remains essential for optimal growth management. The pediatric patient on r-hGH therapy will benefit from these innovations to enhance adherence and optimize long-term response. Keywords: behavioral support, data, digital, growth, participatory medicine Adherence to a therapeutic regimen is an essential component of the success of any prescribed therapy. In the case of treatment of pediatric growth disorders, prescribed therapy in the form of recombinant human growth hormone (r-hGH) will generally be started in early childhood when the child presents with short stature and continued for many years. The aim is to normalize height during childhood and adolescence and achieve an adult height consistent with the genetic target of the family. 1 Such a therapeutic regimen, consisting of daily subcutaneous injections lasting for many years, places a considerable psychological and physical burden on the patient to adhere. There is also a pressure on healthcare professionals (HCPs) responsible for this care to induce a beneficial long-term result. 2 Two important considerations linked to good adherence to r-hGH are necessary for optimal outcomes. These are, first, the extent to which the patient's behavior matches agreed recommendations from their HCP and, second, persistence with the therapy, ie lack of discontinuation. 3 Adherence can be defined as the extent to which the patient follows a prescribed therapeutic regimen and, in the case of r-hGH, the extent to which daily r-hGH injections are taken. The success of r-hGH therapy, as in other chronic conditions, is thought to be dependent on the patient's ability to maximally adhere to their treatment regimen. 2,3 In this review, we will discuss the challenges, both to the patient and HCP, of maintaining a high level of adherence to r-hGH, and the factors which have been shown to influence adherence both negatively and positively. We will summarize feedback data from both HCPs and patients, and discuss knowledge from other more advanced therapeutic areas regar -Abstract Truncated-
medicine, general & internal